Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

D1 Dopamine Receptor Antibodies

Close filters
No results were found for the filter!
NEW
pT354-D1 (phospho-Dopamine Receptor 1 Antibody)
pT354-D1 (phospho-Dopamine Receptor 1 Antibody)
Threonine354 (T354) is a major phosphorylation site of the D1 receptor. The pT354-D1 antibody detects phosphorylation in response to high-efficacy agonists but not after PKC activation. T354 phosphorylation is a key regulator of D1...
$ 375.00 *
Details
NEW
pS372/pS373-D1 (phospho-Dopamine Receptor 1 Antibody)
pS372/pS373-D1 (phospho-Dopamine Receptor 1...
Serine372/Serine373 (S372/S373) is a major phosphorylation site of the D1 receptor. The pS372/pS373-D1 antibody detects phosphorylation in response to high- and low-efficacy agonists but not after PKC activation. S372/S373...
$ 375.00 *
Details
NEW
Validation of the Dopamine Receptor 1 in transfected HEK293 cells
D1 (non-phospho-Dopamine Receptor 1 Antibody)
The non-phospho-D1 receptor antibody is directed against the distal part of the carboxyl-terminal tail of human D1. It can be used to detect total D1 receptors in Western blots independent of phosphorylation. The non-phospho-D1 antibody...
$ 375.00 *
Details

 

 

D1aHGRSWzWKW1E1

The dopamine D1 receptor belongs to the D1-like subfamily of dopamine receptors. It stimulates cAMP production by coupling to stimulatory G proteins. The classical view of dopamine receptor signaling implies that the D1 receptor stimulates the cAMP/PKA/DARPP-32 pathway. Moreover, D1 receptor-mediated PKA activation also results in the activation of the extracellular signal-regulated kinases 1/2 (Erk1/2) by two mechanisms: src-Shp2-dependent Erk1/2 phosphorylation and DARPP-32-mediated inhibition of protein phosphatase-1. It is believed that upregulation of these mechanisms, leading to aberrant Erk1/2 activation, are involved in the development of L-DOPA-induced dyskinesias in animal models of Parkinson’s disease. D1 desensitization, trafficking and signaling are regulated by phosphorylation of carboxyl-terminal threonine354 (pT354-D1), serine372/serine373 (pS372/pS373-D1). This nomenclature refers to the human D1. This phosphorylation motif is also present in mice and rats. For more information on D1 receptor pharmacology please refer to the IUPHAR database. For further reading refer to:

Undieh AS. Pharmacology of signaling induced by dopamine D(1)-like receptor activation. Pharmacol Ther. 2010 Oct;128(1):37-60. doi: 10.1016/j.pharmthera.2010.05.003. Epub 2010 Jun 12. PMID: 20547182; PMCID: PMC2939266.

Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011 Mar;63(1):182-217. doi: 10.1124/pr.110.002642. Epub 2011 Feb 8. PMID: 21303898.

Beaulieu JM, Espinoza S, Gainetdinov RR. Dopamine receptors - IUPHAR Review 13. Br J Pharmacol. 2015 Jan;172(1):1-23. doi: 10.1111/bph.12906. PMID: 25671228; PMCID: PMC4280963.

    The dopamine D1 receptor belongs to the D1-like subfamily of dopamine receptors. It stimulates cAMP production by coupling to stimulatory G proteins. The classical view of... read more »
Close window
D1 Dopamine Receptor Antibodies

 

 

D1aHGRSWzWKW1E1

The dopamine D1 receptor belongs to the D1-like subfamily of dopamine receptors. It stimulates cAMP production by coupling to stimulatory G proteins. The classical view of dopamine receptor signaling implies that the D1 receptor stimulates the cAMP/PKA/DARPP-32 pathway. Moreover, D1 receptor-mediated PKA activation also results in the activation of the extracellular signal-regulated kinases 1/2 (Erk1/2) by two mechanisms: src-Shp2-dependent Erk1/2 phosphorylation and DARPP-32-mediated inhibition of protein phosphatase-1. It is believed that upregulation of these mechanisms, leading to aberrant Erk1/2 activation, are involved in the development of L-DOPA-induced dyskinesias in animal models of Parkinson’s disease. D1 desensitization, trafficking and signaling are regulated by phosphorylation of carboxyl-terminal threonine354 (pT354-D1), serine372/serine373 (pS372/pS373-D1). This nomenclature refers to the human D1. This phosphorylation motif is also present in mice and rats. For more information on D1 receptor pharmacology please refer to the IUPHAR database. For further reading refer to:

Undieh AS. Pharmacology of signaling induced by dopamine D(1)-like receptor activation. Pharmacol Ther. 2010 Oct;128(1):37-60. doi: 10.1016/j.pharmthera.2010.05.003. Epub 2010 Jun 12. PMID: 20547182; PMCID: PMC2939266.

Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011 Mar;63(1):182-217. doi: 10.1124/pr.110.002642. Epub 2011 Feb 8. PMID: 21303898.

Beaulieu JM, Espinoza S, Gainetdinov RR. Dopamine receptors - IUPHAR Review 13. Br J Pharmacol. 2015 Jan;172(1):1-23. doi: 10.1111/bph.12906. PMID: 25671228; PMCID: PMC4280963.

Recently viewed